Your gateway to a free society
Article

The Horrifying Endgame in Ukraine

Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Feb 26, 2026 / Dave DeCamp
House To Vote on Iran War Powers Next Week as Trump Has US on Brink of a Major Conflict
Democrats in the House and Senate vowed on Thursday that they will hold a vote next week on War Powers Resolutions aimed at blocking President Trump from launching an attack on Iran without congressional authorization, as required by the US Constitution. Contact your representatives in the House and tell them to support H.Con.Res. 38 to prevent […]
Read more
Apr 20, 2026 / Tyler Durden
FBI Director Kash Patel Files $250 Million Defamation Lawsuit Against The Atlantic, Reporter
FBI Director Kash Patel Files $250 Million Defamation Lawsuit Against The Atlantic, Reporter FBI Director Kash Patel filed a $250 million defamation lawsuit Monday against The Atlantic magazine and its national-security reporter Sarah Fitzpatrick, escalating a high-profile clash over a Friday article that alleged Patel's "erratic behavior,” excessive drinking, and unexplained absences have alarmed colleagues and raised national-security concerns. FBI Director Kash Patel speaks during a news conference at the Department of Justice on Dec. 4, 2025. Daniel Heuer/AFP In the complaint, filed in U.S. District Court for the District of Columbia,...
Read more
Feb 24, 2026 / Tyler Durden
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space. Jamey Millar, Novo's head of U.S. operations, was quoted by Bloomberg as saying the company set a monthly price of $675 for its family of semaglutide drugs,...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.

Support the liberty movement